Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study.
Publication: Journal of Clinical Oncology
Abstract
7535
Background: cHL is characterized by amplification at 9p24.1, causing overexpression of PD-1 ligands. Thus, cHL may be uniquely sensitive to PD-1 blockade. Nivo is a fully human IgG4 immune checkpoint inhibitor targeting PD-1 that showed promising results in a phase 1b study (NCT01592370) in pts with relapsed/refractory cHL (Ansell SM et al NEJM 2015;372:311–9), who currently have limited treatment options. Methods: This study evaluated the efficacy and safety of nivo in pts with cHL who had received BV after failed ASCT, as Cohort B of the larger Phase 2 Checkmate 205 study (NCT02181738). Nivo was given at 3 mg/kg IV q2w. Response was assessed by independent radiologic review committee (IRRC) and investigators (Inv), using 2007 IWG criteria. Primary endpoint was IRRC ORR. Results: The main characteristics of 80 treated cHL pts were: median age 37 y, median (range) 4 prior regimens (3–15). 90% of pts had drug-related AEs: 25% G3–4, 1% G5 (multi-organ failure). Most common drug-related AEs were fatigue (25%), infusion reaction (IR; 20%) and rash (16%). Most common SAEs were pyrexia, tumor progression, arrhythmia, IR, septic meningitis, and pneumonia ( ≤ 4% each). Select immune-related AEs, all G1–2, occurred in 26%. At database lock (DBL; October 2015), median (range) follow-up was 8.9 mo (1.9–11.7). 64% of pts remained on therapy; main reason for discontinuation was disease progression (16%). IRRC ORR (95% CI) was 66% (54.8–76.4); CR and PR rates were 8.8% (3.6–17.2) and 57.5% (45.9–68.5), respectively. Inv ORR, a pre-specified secondary endpoint, was 73% (61.4–81.9); CR and PR rates were 27.5% (18.1–38.6) and 45.0% (33.8–56.5). 62% (33/53) of IRRC responders remained in response at DBL. 6 pts elected to stop nivo and undergo stem cell transplant, all of these pts were alive at data cut-off. IRRC 6-mo PFS was 77%; OS was 99%. In 43 pts who had no prior BV response, nivo treatment resulted in an IRRC ORR of 72% (31/43). Conclusions: Nivo demonstrated a high response rate, long-lasting responses, and an acceptable safety profile in pts with cHL after ASCT and BV, including pts with no prior BV response. PFS and OS are encouraging in this heavily pretreated population. Clinical trial information: NCT02181738.
Information & Authors
Information
Published In
Copyright
© 2016 by American Society of Clinical Oncology.
History
Published online: May 20, 2016
Published in print: May 20, 2016
Authors
Metrics & Citations
Metrics
Altmetric
Citations
Article Citation
Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study.. JCO 34, 7535-7535(2016).
Download Citation
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Journal of Clinical Oncology 2016 34:15_suppl, 7535-7535
Journal of Clinical Oncology 2016 34:15_suppl, 7535-7535
View Options
View options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.
Subscribe
Subscribe to this Journal
Renew Your Subscription
Become a Member